RECRUITING

Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Early diabetic kidney disease (DKD) occurs in 50-70% of youth with type 2 diabetes (T2D) and confers high lifetime risk of dialysis and premature death. Youth-onset T2D typically manifests during or shortly after puberty in adolescents with obesity. Epidemiological data implicate puberty as an accelerator of kidney disease in youth with obesity and diabetes and the investigators posit that the link between puberty and T2D-onset may explain the high burden of DKD in youth-onset T2D. A better understanding of the impact of puberty on kidney health is needed to promote preservation of native kidney function, especially in youth with T2D.

Official Title

PANTHER Study: Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress

Quick Facts

Study Start:2021-09-27
Study Completion:2027-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05008276

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:8 Years to 14 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. * HbA1c ≥6.0% for untreated high-risk group
  2. * BMI ≥ 95th %ile for high-risk group
  3. * Normal HbA1c ≤5.6% for control group
  4. * Type 1 diabetes (T1D) Antibody negative
  1. * History of Chronic kidney disease (CKD) or acute kidney injury (AKI)
  2. * Metabolic disorder prohibiting safe fasting
  3. * Iodine or penicillin allergy
  4. * Pregnancy
  5. * Thrombophilia
  6. * MRI contraindications
  7. * Hormone therapy

Contacts and Locations

Study Contact

Petter Bjornstad, MD
CONTACT
720-777-4659
Petter.M.Bjornstad@cuanschutz.edu

Principal Investigator

Petter Bjornstad, MD
PRINCIPAL_INVESTIGATOR
University of Colorado School of Medicine

Study Locations (Sites)

Children's Hospital Colorado
Aurora, Colorado, 80045
United States

Collaborators and Investigators

Sponsor: University of Colorado, Denver

  • Petter Bjornstad, MD, PRINCIPAL_INVESTIGATOR, University of Colorado School of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-09-27
Study Completion Date2027-12-01

Study Record Updates

Study Start Date2021-09-27
Study Completion Date2027-12-01

Terms related to this study

Additional Relevant MeSH Terms

  • Type 2 Diabetes Mellitus
  • Diabetic Kidney Disease
  • Adolescent Obesity
  • Pre Diabetes
  • Kidney Hypoxia
  • Puberty